Sitemap
Pages
- About us
- Advocacy
- Blog
- Case Studies & Presentations
- Case Study February 2018
- Clinical Trials
- Contact us
- E-News
- Guidelines
- Join the UKMF
- Legal notice
- Links
- Login
- Myeloma Reports
- Research Directory
- Search
- Sitemap
- Travel Bursaries
- UK Myeloma Research Alliance
- UKMF
- UKMF Meetings
- UKMF/BSH Guidelines
- Webcasts
Meetings
- Autumn Day 2021
- Spring Day 2022
- Autumn Day 2021
- Spring Day 2021
- Scientific Workshop 2020
- Autumn Day 2020
- Scientific Workshop 2020
- Autumn Day 2019
- Scientific Workshop 2019
- Autumn Day 2018
- Scientific Workshop 14 March 2018
- Autumn Day 2017
- 1st Oxford Myeloma Workshop
- UKMF Autumn Day - 9th November 2017
- BSH/ UKMF Symposium - April 2016, Glasgow
- Autumn Day - 9th November 2016
- UKMF Spring Day 2017
- UKMF Autumn Day 2016
- UKMF Spring Day 2016
- UKMF Autumn Day 2015
- UKMF Spring Day 2015
- Autumn Day 2014
- UK Myeloma Forum Spring Day 2014
- UK Myeloma Forum Spring Day
- UK Myeloma Forum Autumn Day
- UK Myeloma Forum Education Day
- UK Myeloma Forum Scientific Day
- UK Myeloma Forum Education Day
- UK Myeloma Forum Autumn Meeting
- UK Myeloma Forum Scientific Day
Links
- Cancer Research UK
- Multiple Myeloma Research Foundation
- Medical Research Council
- Lymphoma Info
- Lymphoma Research Foundation
- Lymphoma Association
- Leukaemia Lymphoma Research
- Leukemia & Lymphomia Society
- International Society for Cellular Therapy
- International Society of Hematology
- International Myeloma Foundation
- Myeloma UK
- European Society for Medical Oncology
- Current Controlled Trials Register
- British Society of Haematology
- British Society for Blood and Marrow Transplantation
- British Committee for Standards in Haematology
- British National Lymphoma Investigation (BNLI)
- Blood Online
- Amyloidosis Support Network
- Hematology
- ASCO
Guidelines
- Lenalidomide Maintenance in multiple myeloma: NICE Guidance
- Option to give second-line ixazomib with lenalidomide and dexamethasone for patients who are neither refractory to previous proteasome inhibitor-based treatment nor to lenalidomide- based treatment if contained within the first line of therapy already received
- Interim treatment change options for the COVID-19 endorsed by NHS England (09 April 2020)
- COVID-19 Guidance
- Screening and Management of Late and Long-term Consequences of Myeloma and its Treatment 2017
- Use of Imaging in the management of patients with myeloma 2017
- Management of AL Amyloidosis 2014
- Diagnosis and Investigation of AL Amyloidosis 2014
- Updates to the guidelines for the diagnosis and management of multiple myeloma
Sponsors
- GSK
- Adaptive Biotechnologies
- Sanofi Genzyme
- Sebia
- Karyopharm Therapeutics Inc
- Takeda Oncology
- Amgen
- Binding Site
- Janssen
- Celgene-BMS
- Myeloma UK
Winners
- ASH Virtual 2020
- IMW 2019, Boston
- EHA Stockholm 2018
- IMW Rome Winning Abstracts
- ASH 2013 New Orleans
- IMW Travel Grant Winners 2013 Kyoto
- ASH 2012 Atlanta Winning abstracts
Maps
- Birmingham
- Dr Cathy Williams
- Newcastle - Graham Jackson
- Wessex - Fiona Ross
- Plymouth - Lyn MaCallum
- London - Kwee Yong
- London - Faith Davies
- London - Gareth Morgan
- London - Steve Schey
- London - Jamie Cavenagh
- Leeds - Gordon Cook
- Leeds - Roger Owen
- Sheffield - Andy Chantry
- Sheffield - Sam Ahmedzai
- Sheffield
- Birmingham
Myeloma reports
- EHA Virtual 2021
- ASH virtual 2020
- EHA Virtual 2020
- ASH 2019 Orlando
- IMW Boston 2019
- EHA Review June 2019
- ASH 2018 San Diego
- EHA Stockholm June 2018
- ASH 2017 Atlanta
- Review IMW 2017
- ASH 2016 Review
- ASH 2015 Review
- Journal Club January 2017 Roundup
- IMW 2013 Review
- ASH 2012 report by Aristeidi Chaidos
- Report from ASH 2013
- Denosumab, anti-RANKL monoclonal antibody, an additional weapon against myeloma bone disease; accumulating evidence
- What hope is there for myeloma bone disease?
- CD48 as a target for antibody therapy in multiple myeloma
- CyBorD superior to RD and CRD in newly diagnosed multiple myeloma but note increased neurop
- Report on the Multiple Myeloma & Related Malignancies Meeting, Bari, Nov 2011
- Targeting adhesion molecules in myeloma – (Podar et al, BJH Nov-II, 2011)